Medacta Group SA (SWX:MOVE)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 2.95B |
| Revenue (ttm) | 636.66M |
| Net Income (ttm) | 88.88M |
| Shares Out | 19.91M |
| EPS (ttm) | 4.45 |
| PE Ratio | 33.35 |
| Forward PE | 30.40 |
| Dividend | 1.10 (0.74%) |
| Ex-Dividend Date | May 7, 2026 |
| Volume | 12,592 |
| Average Volume | 12,466 |
| Open | 151.00 |
| Previous Close | 148.40 |
| Day's Range | 145.20 - 151.00 |
| 52-Week Range | 128.00 - 177.20 |
| Beta | 1.09 |
| RSI | 38.71 |
| Earnings Date | Sep 9, 2026 |
About Medacta Group
Medacta Group SA develops, manufactures, and distributes orthopedic and neurosurgical medical devices Latin America, North America, the Asia-Pacific, and Middle East and Africa. It offers personalized 3D planning tools for use in hip, knee, shoulder, joint replacement, sports medicine, and spine surgery. The company was founded in 1958 and is headquartered in Castel San Pietro, Switzerland. [Read more]
Financial Performance
In 2025, Medacta Group's revenue was 683.83 million, an increase of 15.79% compared to the previous year's 590.58 million. Earnings were 95.46 million, an increase of 30.97%.
Financial numbers in EUR Financial StatementsNews
Medacta Group SA (XSWX:MOVE) Full Year 2025 Earnings Call Highlights: Robust Growth and ...
Medacta Group SA (XSWX:MOVE) Full Year 2025 Earnings Call Highlights: Robust Growth and Strategic Investments
Full Year 2025 Medacta Group SA Earnings Call Transcript
Full Year 2025 Medacta Group SA Earnings Call Transcript
Medacta Group Earnings Call Transcript: H2 2025
Revenue grew 18.5% in constant currency to EUR 684 million, with net profit up 31% to EUR 95.5 million and a proposed 60% dividend increase. 2026 guidance targets 10%-14% revenue growth and gradual margin expansion, supported by innovation and global expansion.
Medacta Group Earnings Call Transcript: Q4 2025
Revenue grew 18.5% in constant currency, exceeding guidance, with strong performance across all regions and business lines. Knee sales surpassed hip for the first time, and the Parcus acquisition boosted extremities. FX headwinds in APAC and a U.S. spine sales transition were noted.
Medacta Group Earnings Call Transcript: H1 2025
H1 2025 saw revenue up 19.8% and net profit up 58% year-over-year, with all business lines and geographies delivering strong, above-market growth. Adjusted EBITDA margin rose to 29.6%, and guidance for 2025 targets 16–18% revenue growth and a 28% margin.
Medacta Group Earnings Call Transcript: H1 2025
H1 2025 revenue grew nearly 20% year-over-year, with strong performance across all regions and product lines. Upgraded 2025 and midterm guidance reflects sustained momentum, robust innovation, and no tariff impact, supported by strong cash flow and low leverage.
Medacta Group Earnings Call Transcript: H2 2024
Revenue grew 16% to over EUR 590 million, with net profit up 54% and a 28% EBITDA margin. All segments outperformed the market, and 2025 guidance targets 13%-15% revenue growth and 27% EBITDA margin, including the Parcus acquisition.
Medacta Group Earnings Call Transcript: H2 2024
Revenue grew 16.2% to €590.6M in 2024, led by strong innovation in knees, extremities, and spine. SpheriKA and NextAR technologies drove segment outperformance, with robust growth in North America and ASCs. Tariff risks are manageable, and momentum is expected to continue.
Medacta Group Transcript: H1 & CMD 2024
H1 2024 saw 14.6% revenue growth, strong gains in knees and shoulders, and a 30% net profit increase. Guidance targets 13%-15% top-line growth for 2024 and low double-digit CAGR through 2027, with margins stable and CapEx closely tied to growth.
Medacta Group Earnings Call Transcript: H1 2024
H1 2024 saw 14.3% constant currency revenue growth, led by strong Knee and Shoulder performance and robust gains in Europe, APAC, and North America. Guidance for 13%-15% growth is confirmed, with a strong H2 pipeline expected from recent marketing and education investments.